Generic Sterile Injectables Market, by Drug Type (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines, Immunoglobulins, Blood Factors, Antibiotics, and Others), by Therapeutic Application (Cancer, Metabolic Diseases, Cardiovascular Diseases, Central Nervous System Disease, Infectious Disorders, Musculoskeletal Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Mar 2024

Code : CMI519

Pages :387

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Recent Developments

In March 2023, Hikma Pharmaceuticals PLC, a multinational pharmaceutical company, announced the launch of four new sterile injectable medicines in Canada, providing crucial new treatment options for patients and healthcare professionals while also expanding the company's presence in the Canadian market. All of the drugs are the first or second generic versions of their compounds on the Canadian market, and these treat illnesses in a wide range of therapeutic areas, representing a significant increase in access to medicines for Canadian patients.
In May 2022, Endo International plc, a generics and specialty branded pharmaceutical company, announced that its subsidiary Endo Ventures Limited (EVL) had acquired six development-stage, ready-to-use injectable product candidates from Nevakar Injectables Inc., a subsidiary of Nevakar, Inc. The product candidates are in various phases of development, with the first launch anticipated for 2025. Endo now has control over all remaining development, approval, launch, and commercialization efforts for these pharmaceutical candidates following the acquisition.
In March 2022, Nevakar Injectables Inc., a biopharmaceutical company developing multiple sterile injectable products, announced the launch of its ready-to-use Ephedrine Sulfate Injection ("Ephedrine"), a formulation pre-diluted to a 5mg/mL concentration and supplied in a 10mL vial. The product will be marketed and sold in the U.S. by the Par Sterile Products ("Par") business of Endo International plc., a generics and specialty branded pharmaceutical company. Ephedrine is a widely used injectable vasopressor agent that is indicated for the treatment of clinically important hypotension occurring during surgery.
In September 2020, Strides Pharma Science Limited, a global pharmaceutical company, announced an investment in SteriScience Pharma Private Limited to establish the company's dedicated arm for the global sterile injectables market. Furthermore, SteriScience Pharma Private Limited has formed a joint venture ('JV') with Brooks Laboratories Limited ('Brooks') to establish a strong carbapenem company with integrated production capabilities.